Dostarlimab, a monoclonal antibody drug, smashed expectations in a recent trial run by Memorial Sloan Kettering Cancer Center in New York, sponsored by pharmaceutical giant GlaxoSmithKline (GSK). We
A year after the trial’s completion, each of the 18 participants had their disease go into complete remission, with doctors unable to find signs of the cancer in their body.
‘I believe this is the first time this has happened in the history of cancer,’ said Dr Luis Diaz, one of the lead authors of the paper and an oncologist at the Memorial Sloan Kettering Cancer Center.
‘It’s really exciting,’ said Diaz, a member of the White House’s National Cancer Advisory Board.
‘I think this is a great step forward for patients.’
He told the New York Times the discovery was ‘the tip of the iceberg.’
While the trial was small, it is considered game-changing, and sets up the drug as a potential cure for one of the most dangerous common cancers known.
‘We are investigating if this same method may help other cancers where the treatments are often life-altering and tumors can be MMRd,’ he said.
‘We are currently enrolling patients with gastric (stomach), prostate, and pancreatic cancers.’